Physician profile
Steven N Poling
NPI 1154304269
$1,131.70
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $146 · 2021: $144 · 2022: $280 · 2023: $382 · 2024: $44.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $200.42 | 2022-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $95.16 | 2021-2023 | Steglatro, Belsomra |
| Arbor Pharmaceuticals, INC. | $84.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.43 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.43 | 2021-2022 | |
| Axsome Therapeutics, INC. | $64.04 | 2022-2023 | Sunosi |
| Jazz Pharmaceuticals INC. | $55.82 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.39 | 2022-2023 | |
| Amgen INC. | $39.94 | 2019 | |
| Redhill Biopharma INC. | $37.86 | 2020 | |
| Azurity Pharmaceuticals, INC. | $37.47 | 2023 | Edarbi, Horizant |
| Lilly USA, LLC | $34.54 | 2023 | Mounjaro |
| Endo Pharmaceuticals INC. | $29.17 | 2019-2021 | |
| Gilead Sciences, INC. | $29.17 | 2019-2020 | |
| Amarin Pharma, INC. | $28.75 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.34 | 2022 | |
| Trilliant Surgical LLC. | $22.17 | 2023 | Arsenal Sinus Support Plate |
| Janssen Pharmaceuticals, INC | $16.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.29 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $16.26 | 2023 | |
| Sanofi Pasteur INC. | $15.45 | 2023 | |
| Novo Nordisk INC | $15.32 | 2022 | |
| Braintree Laboratories, INC. | $15.09 | 2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $13.89 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.27 | 2020 | |
| Echosens North America, INC. | $7.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.